[Targeting the PD-1/PD-L1 immune checkpoint signal - a new treatment strategy for cancer]

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Tumor cells employ cancer immune escape mechanisms within the tumor microenvironment.
• The programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway is a critical immune checkpoint mediating immunosuppression.
• PD-1 is primarily on T cells, while PD-L1 is often on tumor cells, inhibiting anti-tumor immune responses.

Purpose of the Study:

• To provide a background on the PD-1/PD-L1 signaling pathway.
• To review foreign clinical trials investigating PD-1/PD-L1 blockade for cancer treatment.
• To present findings from a clinical trial conducted within the department.

Main Methods:

• Review of existing literature on PD-1/PD-L1 pathway and cancer immune escape.
• Analysis of data from previously performed international clinical trials.
• Description of a specific clinical trial conducted at the department.

Main Results:

• Inhibition of the PD-1/PD-L1 interaction enhances T-cell mediated anti-tumor activity.
• Clinical trials demonstrate the efficacy of PD-1/PD-L1 blockade in solid and hematological malignancies.
• Anti-PD-1 therapies are nearing completion for drug production.

Conclusions:

• The PD-1/PD-L1 pathway is a significant target for cancer immunotherapy.
• Blocking PD-1/PD-L1 interactions offers a promising strategy for enhancing anti-tumor immunity.
• Further clinical evaluation and therapeutic development are ongoing.